Latest osteosarcoma Stories
NEW YORK, Aug. 2, 2011 /PRNewswire-USNewswire/ -- A paper in the Journal of Dental Research by dentist Chester Douglass and colleagues, "An Assessment of Bone Fluoride and Osteosarcoma," (7/28/11) claims to show no association between fluoride bone levels and osteosarcoma, a form of bone cancer.
A new University of Minnesota discovery may help bone cancer patients fight their disease more effectively, according to new research published in the September issue of Bone.
The International and American Associations for Dental Research have released in its Journal of Dental Research a study that investigated bone fluoride levels in individuals with osteosarcoma, which is a rare, primary malignant bone tumor that is more prevalent in males.
CHICAGO, July 28, 2011 /PRNewswire-USNewswire/ -- A new study in the Journal of Dental Research finds bone fluoride levels are not associated with osteosarcoma, a rare bone cancer more prevalent in males.
WEST CHESTER, Pa. and INDIANAPOLIS, June 9, 2011 /PRNewswire/ -- Synthes, Inc.
A new study into osteosarcoma - cancer of the bone - will use advances in genomic research and analysis to identify new genes that give rise to the condition and to create personalised blood tests for children and young adults with the condition.
INDIANAPOLIS, May 27, 2011 /PRNewswire/ -- In the press release, "Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcomas," issued May 19, 2011, by Eli Lilly and Company (NYSE: LLY), the following sentence has been amended to: The best overall responses were as follows: one partial response in the Ewing sarcoma tier (n=1); and no partial responses, but stable disease of 41 percent (n=9) in leiomyosarcoma; 35 percent (n=6) in synovial sarcoma; 28 percent (n=5) in Ewing family of...
INDIANAPOLIS, May 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from connective tissues in the body.
INDIANAPOLIS, March 17, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that patients should not use the alcohol prep pads made by the Triad Group that are contained in the black starter kits for ForteoÂ® [teriparatide (rDNA origin) injection] in the United States.
SAN MARINO, Calif., Feb. 28, 2011 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) announced today that the U.S.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).